𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Psychosis in Parkinson's disease

✍ Scribed by Werner Poewe

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
79 KB
Volume
18
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.

πŸ“œ SIMILAR VOLUMES

Clozapine for psychosis in Parkinson's d
Clozapine for psychosis in Parkinson's disease
✍ Dr. Ronald F. Pfeiffer; Jasbir Kang; Benjamin Graber; Ruth Hofman; James Wilson πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 321 KB πŸ‘ 1 views

## Abstract The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because

Reply: Rebound psychosis in Parkinson's
Reply: Rebound psychosis in Parkinson's disease
✍ Hubert H. Fernandez; Michael S. Okun πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 35 KB πŸ‘ 1 views

## Abstract The original letter to which this reply refers was published in __Movement__ DisordersMov Disord (2005) 20 (4) 515.

The neurochemical mechanism of rebound p
The neurochemical mechanism of rebound psychosis in Parkinson's disease
✍ Spiridon Papapetropoulos; Deborah C. Mash πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 35 KB πŸ‘ 1 views

## Abstract A reply to this letter has been published in __Movement__ DisordersMov Disord (2005) 20 (4) 515.

Scales to assess psychosis in Parkinson'
Scales to assess psychosis in Parkinson's disease: Critique and recommendations
✍ Hubert H. Fernandez; Dag Aarsland; Gilles FΓ©nelon; Joseph H. Friedman; Laura Mar πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 1 views

## Abstract Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer‐reviewed rating psychosis scales used in PD psychosis st

Rebound psychosis: Effect of discontinua
Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease
✍ Hubert H. Fernandez; Martha E. Trieschmann; Michael S. Okun πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 44 KB

## Abstract To determine whether psychiatrically stable patients with a history of drug‐induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on‐going psychosis, to be slow